- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2090-6226
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Novel biomarkers assist in detection of liver fibrosis in HCV patients ; volume:11 ; number:1 ; day:23 ; month:11 ; year:2021 ; pages:1-5 ; date:12.2021
Egyptian liver journal ; 11, Heft 1 (23.11.2021), 1-5, 12.2021
- Urheber
-
Addissouky, Tamer A.
Wang, Yuliang
Megahed, Fayed Attia Koutb
Agroudy, Ayman E. El
Sayed, Ibrahim El Tantawy El
El-Torgoman, Abdel Moneim A. K.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43066-021-00156-x
- URN
-
urn:nbn:de:101:1-2022013020163541478327
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Addissouky, Tamer A.
- Wang, Yuliang
- Megahed, Fayed Attia Koutb
- Agroudy, Ayman E. El
- Sayed, Ibrahim El Tantawy El
- El-Torgoman, Abdel Moneim A. K.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fibrosis remodelling and ECM biomarkers in liver fibrosis
Serum biomarkers for liver fibrosis assessment
Evaluation of HCV-related liver fibrosis post-successful DAA therapy
Drug induced liver injury : can biomarkers assist RUCAM in causality assessment?
Immuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexus
Genetic-driven biomarkers for liver fibrosis through bioinformatic approach
Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
HCV and related liver diseases
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia
HCV, oxidative stress and liver disease
Fibrosis remodelling and ECM biomarkers in liver fibrosis
Serum biomarkers for liver fibrosis assessment
Evaluation of HCV-related liver fibrosis post-successful DAA therapy
Drug induced liver injury : can biomarkers assist RUCAM in causality assessment?
Immuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexus
Genetic-driven biomarkers for liver fibrosis through bioinformatic approach
Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
HCV and related liver diseases
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia
HCV, oxidative stress and liver disease
Fibrosis remodelling and ECM biomarkers in liver fibrosis
Serum biomarkers for liver fibrosis assessment
Evaluation of HCV-related liver fibrosis post-successful DAA therapy
Drug induced liver injury : can biomarkers assist RUCAM in causality assessment?
Immuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexus
Genetic-driven biomarkers for liver fibrosis through bioinformatic approach
Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
HCV and related liver diseases
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia